20 Years since human immunodeficiency virus discovery: Considerations for the next decade

Pharmacotherapy

Volumn 23, Issue 3, 2003, Pages 384-387

  Idemyor, Vincent ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; EPIDEMIOLOGICAL DATA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMORY CELL; PATIENT COMPLIANCE; REVIEW; SEROPREVALENCE; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS INHIBITION; VIRUS LOAD; VIRUS PATHOGENESIS;

EID: 0037369996     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.3.384.32113     Document Type: Review

References (11)

1. Centers for Disease Control and Prevention. Pneumocystis pneumonia - Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2.
2. Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999; 397:436-41.
3. sm) closely related to HIV-2. Nature 1989;339:389-92.
4. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response lymphoid tissue to antiretroviral therapy of HIV-1 infection. Science 1997;276:960-4.
5. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387:188-91.
6. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300.
7. United States Department of Health and Human Services, Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for use of antiretroviral agents in HIV-infected adults and adolescents, February 2, 2002. Available from www.hivatis.org. Accessed November 4, 2002.
8. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279:1977-83.
9. Little SJ, Holte S, Routy JP, et al. Antiretroviral resistance and response to initial therapy among recently HIV-infected subjects in North America. Antivir Ther 2001;6(suppl 1):21.
10. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002;296:2354-60.
11. Population Council. Bill & Melinda Gates Foundation supports clinical trials of Population Council's lead candidate AIDS-fighting microbicide, February 2, 2002 [press release]. Available from http://biz.yahoo.com/020202/22000_l.html. Accessed April 2002.